As the year draws to a close, it is a great moment to look back on a set of clinical recommendations and best-practice guidelines, published earlier this year, that provide an important update on the diagnosis, management, and long-term care of Multiple Endocrine Neoplasia type 1 (MEN1). These guidelines bring together the latest evidence and expert consensus to support more consistent, high-quality care across centres.
The document emphasises that MEN1 is a complex, multi-tumour condition, and although genomic sequencing has improved the detection of MEN1 pathogenic variants, early clinical recognition remains essential to preventing complications and improving outcomes.
The guideline outlines updated recommendations on surveillance intervals, biochemical monitoring, and appropriate imaging strategies, aiming to support earlier detection and timely intervention. It also highlights advances in tumour biology research that may open new avenues for tailored therapies in the future.
Importantly, many of the experts contributing to these guidelines work at Endo-ERN member institutions, underscoring the network’s central role in advancing high-quality, standardised care pathways for rare endocrine diseases across Europe.
Overall, these best-practice recommendations reinforce the need for lifelong, multidisciplinary, and well-coordinated care for MEN1, while pointing toward promising developments that may continue to improve outcomes for patients in the coming years.
